What question did this study set out to answer?

Summarize rational design strategies, structural classifications, and inhibitory mechanisms of peptides and peptoids targeting amyloid-β aggregation in Alzheimer’s disease.

August 28, 2026Bioconjugate Chemistry

Rationally Designed Peptides and Peptoids as Inhibitors of Amyloid-β (Aβ) Aggregation

View Full Paper

Ask AI

Bookmark

Authors

XHXiaoping Huang SMSijie Ma XLXiang Li

Discussion

Member takes

Overview

Review reveals design strategies of peptides and peptoids inhibiting amyloid-β aggregation in Alzheimer's disease models, highlighting novel therapeutic avenues for neurodegeneration.

Key Points

Summarize rational design strategies, structural classifications, and inhibitory mechanisms of peptides and peptoids targeting amyloid-β aggregation in Alzheimer’s disease.
Reviewed literature on peptidomimetic therapeutics designed to block amyloid-β aggregation in Alzheimer's disease.
Categorized peptide-based inhibitors into natural sequence-derived, non-natural sequence-based, and small molecule conjugates across chronological development.
Identified peptidomimetics as promising anti-amyloid agents owing to their favorable biocompatibility, low intrinsic toxicity, and structural adaptability.
Summarized design strategies across natural, non-natural, and small-molecule hybrid classes, detailing structural modifications that enhance inhibitory efficacy against amyloid fibril formation.

Cite This Study

Huang et al. (2026) studied this question.

synapsesocial.com/papers/6a99606eba1957220e75dafd https://doi.org/10.1021/acs.bioconjchem.6c00145

View Full Paper

Ask AI

Bookmark

August 28, 2026Bioconjugate Chemistry

Rationally Designed Peptides and Peptoids as Inhibitors of Amyloid-β (Aβ) Aggregation

View Full Paper

Ask AI

Bookmark

Authors

XHXiaoping Huang SMSijie Ma XLXiang Li

Discussion

Member takes

Overview

Review reveals design strategies of peptides and peptoids inhibiting amyloid-β aggregation in Alzheimer's disease models, highlighting novel therapeutic avenues for neurodegeneration.

Key Points

Summarize rational design strategies, structural classifications, and inhibitory mechanisms of peptides and peptoids targeting amyloid-β aggregation in Alzheimer’s disease.
Reviewed literature on peptidomimetic therapeutics designed to block amyloid-β aggregation in Alzheimer's disease.
Categorized peptide-based inhibitors into natural sequence-derived, non-natural sequence-based, and small molecule conjugates across chronological development.
Identified peptidomimetics as promising anti-amyloid agents owing to their favorable biocompatibility, low intrinsic toxicity, and structural adaptability.
Summarized design strategies across natural, non-natural, and small-molecule hybrid classes, detailing structural modifications that enhance inhibitory efficacy against amyloid fibril formation.

Cite This Study

Huang et al. (2026) studied this question.

synapsesocial.com/papers/6a99606eba1957220e75dafd https://doi.org/10.1021/acs.bioconjchem.6c00145

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark